PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using PI-2620
Recruiting
The investigators will compare PI-2620 tau PET scans from patients with frontotemporal lobar degeneration (FTLD), patients with non-amnestic presentations of Alzheimer's disease (naAD), and demographically matched cognitively normal subjects.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Perelman Center for Advance Medicine, Philadelphia, Pennsylvania
Conditions: Frontotemporal Lobar Degeneration, Alzheimer Disease, Cognitively Normal
SV2A in Older Adults
Recruiting
The aim of the study is to examine the effect of cannabis use on brain synaptic density among older adults using \[11C\]UCB-J PET imaging.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
07/31/2025
Locations: Conneticut Mental Health Center, New Haven, Connecticut
Conditions: Cannabis Use
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Recruiting
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Cancer and Blood Specialty Clinic, Los Alamitos, California +265 locations
Conditions: Relapsed or Refractory Multiple Myeloma
Multi-System Analysis of Opioid Receptor Binding
Recruiting
This study will enroll up to 60 adults (including 30 females and 30 males) in three cohorts of up to 20 subjects each. In all three groups, \[11C\]carfentanil whole-body PET imaging will be used to examine the central nervous system (CNS) and broader systemic opioid binding in an initial scan session. In the two groups not receiving standard of care medication assisted treatment (MAT) for opioid use disorder (OUD) the effects on \[11C\]carfentanil binding potential of the blockade of opioid bind... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
07/31/2025
Locations: University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania
Conditions: Healthy, Opioid Use Disorder
A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
Recruiting
This is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's disease.
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
07/31/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +45 locations
Conditions: Early Alzheimer's Disease
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
Recruiting
The purpose of this study is to evaluate the safety and efficacy of glofitamab, as monotherapy and in combination with a standard chemoimmunotherapy regimen: rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in pediatric and young adult participants with relapsed and refractory (R/R) mature B-cell non-Hodgkin lymphoma (B-NHL).
Gender:
ALL
Ages:
Between 6 months and 30 years
Trial Updated:
07/31/2025
Locations: Children's Hospital of Alabama, Birmingham, Alabama +23 locations
Conditions: Mature B-Cell Non-Hodgkin Lymphoma
WAKIX® (Pitolisant) Pregnancy Registry
Recruiting
The WAKIX (pitolisant) Pregnancy Registry is a US-based, prospective, observational cohort study designed to evaluate the association between pitolisant exposure during pregnancy and subsequent maternal, fetal, and infant outcomes.
Gender:
FEMALE
Ages:
All
Trial Updated:
07/31/2025
Locations: Evidera (PPD), Morrisville, North Carolina
Conditions: Pregnancy Related, Narcolepsy
The Effects of Increasing Caloric Intake on Diet-Induced Thermogenesis and 24h Energy Expenditure
Recruiting
Background: Diet-induced thermogenesis (DIT) is the amount of energy one s body uses to eat food, absorb the nutrients from the food, and process those nutrients. Researchers would like to understand more about how changing the balances of protein, fat, carbohydrates, and total calories in the diet can affect DIT. Objective: To learn how different diets can change a person s DIT. Eligibility: Healthy people aged 18 to 60 years who have not intentionally lost weight in the past 6 months. De... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
07/31/2025
Locations: NIDDK, Phoenix, Phoenix, Arizona
Conditions: Obesity, Normal Physiology, Healthy Volunteers
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
Recruiting
The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Local Institution - 0046, Mobile, Alabama +216 locations
Conditions: Relapsed or Refractory Multiple Myeloma
Speckle Plethysmography Pulse Transit Time as a Marker of Blood Pressure Changes
Recruiting
Background: Blood pressure is one of the key markers of cardiovascular health. High blood pressure, also called hypertension, can increase the risk of heart disease or stroke. Monitoring a person s blood pressure continuously over a 24-hour period at home is the best way to diagnose hypertension, but the equipment currently used to do it is cumbersome. This natural history study will test a new technique for monitoring blood pressure continuously over time. Objective: To test a new technique... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
07/31/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Blood Pressure
MAGNETIC RESONANCE SPECTROSCOPY BIOMARKERS IN TYPE 3 GAUCHER DISEASE (GD3)
Recruiting
Recent studies have has shown that magnetic resonance spectroscopy (MRS) can provide validated neuronal markers in patients with Type 1 GD (GD1) who are on stable therapy. However, alterations in neurometabolites in adult patients with GD3, who have established neurological involvement, are not well understood. The goal of this study is to characterize neurometabolite profiles in adult patients with GD3 using MRS to identify novel biomarkers that can demonstrate treatment response. Additionally,... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/31/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Gaucher Disease, Type 3
Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer
Recruiting
To learn if adding lurbinectedin to the combination of paclitaxel and bevacizumab can help to control advanced cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Ovarian Cancer